%PDF-1.4
%
72 0 obj
<>
endobj
69 0 obj
<>
endobj
142 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-07-09T13:11:53Z
2024-03-19T05:32:40-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-19T05:32:40-07:00
application/pdf
Heather
2003-729.aug
uuid:f174a261-1dd1-11b2-0a00-9108277d8900
uuid:f174a263-1dd1-11b2-0a00-d30000000000
endstream
endobj
58 0 obj
<>
endobj
59 0 obj
<>
endobj
73 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 42 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 44 0 R/Type/Page>>
endobj
14 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 46 0 R/Type/Page>>
endobj
17 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 48 0 R/Type/Page>>
endobj
25 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 50 0 R/Type/Page>>
endobj
33 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 52 0 R/Type/Page>>
endobj
164 0 obj
[168 0 R]
endobj
165 0 obj
<>stream
q
0 0 612 792 re
W n
BT
0.85091 0.85091 0.85091 rg
/T1_0 19 Tf
0.6303 0.7762 -0.7762 0.6303 16.7778 46.0632 Tm
(Personal non-commercial use only. The Journal of Rheumatology. Copyright\
\251 2004. All rights reserved)Tj
ET
Q
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 61 714.4004 Tm
[(2.)-875.1 (Pachman LM, Liotta-Davis MR, Hong DK, et al. )17.7 (TNF)]TJ
/T1_2 1 Tf
0 Tc 0 Tw 23.5794 0 Td
(\002)Tj
/T1_1 1 Tf
-0.00011 Tc [0.1 (-308A)]TJ
0.02499 Tw -21.9044 -1.25 Td
(allele in juvenile dermatomyositis: association with increased)Tj
0 -1.25 TD
(production of tumor necrosis factor alpha, disease duration, and)Tj
T*
[(pathologic calcifications. )54.8 (Arthritis Rheum 2000;43:2368-77.)]TJ
-1.675 -1.25 Td
[(3.)-875.1 (Callen )54.8 (AM, Pachman LM, Hayford JR, Chung )54.8 (A, )]TJ
1.675 -1.25 Td
(Ramsey-Goldman R. Intermittent high-dose intravenous )Tj
T*
[(methylprednisolone \(IV)-257.3 (pulse\) therapy prevents calcinosis and)]TJ
T*
(shortens disease course in juvenile dermatomyositis [abstract].)Tj
T*
(Arthritis Rheum 1994;37 Suppl:R10.)Tj
-1.675 -1.25 Td
[(4.)-875.1 (Fisler RE, Liang MG, Fuhlbrigge RC, )36.8 (Y)99.8 (alcindag )54.8 (A, Sundel RP)110.7 (.)]TJ
1.675 -1.25 Td
(Aggressive management of juvenile dermatomyositis results in)Tj
T*
[(improved outcome and decreased incidence of calcinosis. J )54.8 (Am)]TJ
T*
[(Acad Dermatol 2002;47:505-1)36.8 (1.)]TJ
-1.675 -1.25 Td
[(5.)-875.1 (Klein-Gitelman MS, Pachman LM. Intravenous corticosteroids:)]TJ
1.675 -1.25 Td
(adverse reactions are more variable than expected in children. )Tj
0 Tc T*
(J Rheumatol 1998;25:1995-2002.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(6.)-875.1 (Pachman LM. Imperfect indications of disease activity in juvenile)]TJ
1.675 -1.25 Td
(dermatomyositis. J Rheumatol 1995;2:193-7.)Tj
-1.675 -1.25 Td
[(7.)-875.1 (Bohan )54.8 (A, Peter JB. Polymyositis and dermatomyositis. N Engl )]TJ
0 Tc 1.675 -1.25 Td
(J Med 1975;292:344-7,403-7.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(8.)-875.1 (Maricq H, Leroy C. Patterns of finger capillary abnormalities in)]TJ
1.675 -1.25 Td
[(connective tissue disease by \322widefield\323 microscopy)64.8 (. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 1973;16:619-28.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(9.)-875.1 (Kenik JG, Maricq HR, Bole GG. Blind evaluation of the diagnostic)]TJ
1.675 -1.25 Td
(specificity of nailfold capillary microscopy in the connective tissue)Tj
T*
[(diseases. )54.8 (Arthritis Rheum 1981;24:885-91.)]TJ
-2.175 -1.25 Td
[(10.)-875.1 (Lee P)110.7 (, Sarkozi J, Bookman )54.8 (AA, Keystone EC, )54.8 (Armstronh SK.)]TJ
2.175 -1.25 Td
[(Digital blood flow and nailfold capillary microscopy in Raynaud\325)54.8 (s)]TJ
T*
(phenomenon. J Rheumatol 1986;13:564-9.)Tj
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Silver RM, Maricq HR. Childhood dermatomyositis: serial)]TJ
2.1381 -1.25 Td
(microvascular studies. Pediatrics 1989;83:278-83.)Tj
-2.175 -1.25 Td
[(12.)-875.1 (Nussbaum DI, Silver RM, Maricq HR. Serial changes in nailfold)]TJ
2.175 -1.25 Td
[(capillary morphology in childhood dermatomyositis. )54.8 (Arthritis)]TJ
0 Tc T*
[(Rheum 1983;26:1)36.9 (169-72.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(13.)-875.1 (Pachman LM, Sundber)17.7 (g J, Kinder J, Maduzia L, Daugherty C.)]TJ
2.175 -1.25 Td
(Nailfold capillary studies in children with pediatric connective)Tj
T*
(tissue diseases: systemic lupus erythematosus, juvenile )Tj
T*
[(dermatomyositis, Raynaud\325)54.8 (s phenomenon \321 comparison with data)]TJ
T*
[(from normal children [abstract]. )54.8 (Arthritis Rheum 1996;39)]TJ
0 Tc 0 Tw T*
(Suppl:R14.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(14.)-875.1 (Pachman LM, Sundber)17.7 (g J, Maduzia L, Daugherty C, Litt D.)]TJ
2.175 -1.25 Td
(Sequential studies of nailfold capillary vessels in 10 children with)Tj
T*
(juvenile dermatomyositis: correlation with disease activity score)Tj
T*
[(but not von )17.7 (W)39.8 (illebrand factor antigen [abstract]. )54.8 (Arthritis Rheum)]TJ
0 Tc T*
(1995;38 Suppl:S361.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(15.)-875.1 (Bode RK, Klein-Gitelman MS, Miller ML, Lechman )17.7 (TS, Pachman)]TJ
2.175 -1.25 Td
(LM. Disease activity score for children with juvenile )Tj
T*
[(dermatomyositis: Reliability and validity evidence. )54.8 (Arthritis Care)]TJ
0 Tc T*
(Res 2003;49:7-15.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(16.)-875.1 (Huber )54.8 (AM, Hicks JE, Lachenbruch P)91.7 (A, et al. )17.7 (V)110.8 (alidation of the)]TJ
2.175 -1.25 Td
[(Childhood Health )54.8 (Assessment Questionnaire in the juvenile )]TJ
T*
[(idiopathic myopathies. J Rheumatol 2001;28:1)36.8 (106-1)36.8 (1.)]TJ
-2.175 -1.25 Td
[(17.)-875.1 (Feldman BM, )54.8 (A)91.8 (yling-Campos )54.8 (A, Luy L, Stevens D, Silverman ED,)]TJ
2.175 -1.25 Td
(Laxer RM. Measuring disability in juvenile dermatomyositis:)Tj
T*
[(validity of the Childhood Health )54.8 (Assessment Questionnaire. )]TJ
T*
(J Rheumatol 1995;22:326-31.)Tj
-2.175 -1.25 Td
[(18.)-875.1 (Lundber)17.7 (g I, Nessesmo I, Hedfors E. )54.8 (A)-220.1 (clinical, serological and)]TJ
2.175 -1.25 Td
(histopathological study of myositis patients with and without )Tj
T*
[(anti-RNP)-238.2 (antibodies. Semin )54.8 (Arthritis Rheum 1992;22:127-38.)]TJ
-2.175 -1.25 Td
[(19.)-875.1 (De Benedetti F)79.7 (, De )54.8 (Amici M, )54.8 (Aramini L, Ruperto N, Martini )54.8 (A.)]TJ
2.175 -1.25 Td
(Correlation of serum neopterin concentrations with disease activity)Tj
T*
[(in juvenile dermatomyositis. )54.8 (Arch Dis Child 1993;69:232-5.)]TJ
-2.175 -1.25 Td
[(20.)-875.1 (Pangratis N. Diagnostic investigation using vital capillary)]TJ
2.175 -1.25 Td
[(microscopy and dynamic capillaroscopy)64.8 (. Clin Hemorheol Microcirc)]TJ
0 Tc 0 Tw T*
(1997;17:371-83.)Tj
-0.00011 Tc 0.02499 Tw 30.825 80.0161 Td
[(21.)-875.1 (Blockmans D, Beyens G, )17.7 (V)110.8 (erhaeghe R. Predictive value of nailfold)]TJ
2.175 -1.25 Td
(capillaroscopy in the diagnosis of connective tissue diseases. Clin)Tj
T*
(Rhematol 1996;15:148-53.)Tj
-2.175 -1.25 Td
[(22.)-875.1 (Cannas F)79.7 (, Binaghi F)79.7 (. Nailfold capillaroscopy and laser Doppler)]TJ
2.175 -1.25 Td
(flowmetry during standardised cold challenge to evaluate capillary)Tj
T*
(pattern and digital flow in idiopathic acrocyanosis. Panminerva)Tj
0 Tc T*
(Med 2002;44:123-7.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(23.)-875.1 (Monticone G, Collona L, Palermi G, Bono R, Puddu P)110.7 (. Quantitative)]TJ
2.175 -1.25 Td
(nailfold capillary microscopy findings in patients with acrocyanosis)Tj
T*
(compared with patients having systemic sclerosis and control)Tj
T*
[(subjects. J )54.8 (Am )54.8 (Acad Dermatol 2000;42:787-90.)]TJ
-2.175 -1.25 Td
[(24.)-875.1 (Stauder )54.8 (A, Hunziker )17.7 (T)74 (, Lutolf O, Schmidli J, Chen D, Mahler F)79.7 (.)]TJ
2.175 -1.25 Td
(Quantitative nailfold capillary microscopy in cutaneous and)Tj
T*
(systemic lupus erythematosus and localized and systemic )Tj
T*
[(scleroderma. J )54.8 (Am )54.8 (Acad Dermatol 1991;24:941-5.)]TJ
-2.175 -1.25 Td
[(25.)-875.1 (Ong )36.8 (YY)128.8 (, Nikoloutsopoulos )17.7 (T)74 (,)-0.1 ( Bond CP)110.7 (, Smith MD, )54.8 (Ahern MJ,)]TJ
2.175 -1.25 Td
(Roberts-Thomson PJ. Decreased nailfold capillary density in)Tj
T*
[(limited scleroderma with pulmonary hypertension. )54.8 (Asian Pac )]TJ
T*
[(J )54.8 (Aller)17.7 (gy Immunol 1998;16:81-6.)]TJ
-2.175 -1.25 Td
[(26.)-875.1 (Fahrig C, Breitinger L, Heidrich H. )17.7 (V)59.8 (ital capillary microscopic)]TJ
2.175 -1.25 Td
[(findings in the nailfold of patients with diabetes mellitus. )17.7 (V)110.8 (asa)]TJ
0 Tc 0 Tw T*
(2000;29:258-63.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(27.)-875.1 (Dinc )54.8 (A, Melikogu M, Korkmaz C, Fresko I, \205zdogan H, )36.7 (Y)99.8 (azici H.)]TJ
2.175 -1.25 Td
(Nailfold capillary abnormalities in patients with familial)Tj
T*
[(Mediterranean fever)54.8 (. Clin Exp Rheumatol 2001;19:S42-4.)]TJ
-2.175 -1.25 Td
[(28.)-875.1 (Spencer)19.7 (-Green G, Schlesinger M, Bove KE, et al. Nailfold capillary)]TJ
2.175 -1.25 Td
(abnormalities in childhood rheumatic diseases. J Pediatr)Tj
0 Tc 0 Tw T*
(1979;102:341-6.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(29.)-875.1 (Pachman LM, Mendez E, Kanuru J, Sundber)17.7 (g J, Miller CH, Kinder)]TJ
2.175 -1.25 Td
(J. Nailfold capillary studies in 50 untreated children with juvenile)Tj
T*
[(dermatomyositis [abstract]. )54.8 (Arthritis Rheum 1998;41 Suppl:S265.)]TJ
-2.175 -1.25 Td
[(30.)-875.1 (T)69.9 (ezak Z, Hof)17.7 (fman EP)110.7 (, Lutz JL, et al. Expression profiling in)]TJ
2.175 -1.25 Td
[(DQA1*0501 children with juvenile dermatomyositis: )54.8 (A)-220.1 (novel)]TJ
T*
(model of pathogenesis. J Immunol 2002;168:4154-63.)Tj
-2.175 -1.25 Td
[(31.)-875.1 (Eisenstein DM, Paller )54.8 (AS, Pachman LM. Juvenile dermatomyositis)]TJ
2.175 -1.25 Td
(presenting with rash alone. Pediatrics 1997;100 Pt 1:391-2.)Tj
-2.175 -1.25 Td
[(32.)-875.1 (Plamondon S, Dent PB. Juvenile amyopathic dermatomyositis:)]TJ
2.175 -1.25 Td
[(results of a case finding descriptive survey)64.8 (. J Rheumatol)]TJ
0 Tc 0 Tw T*
(2000;27:2031-4.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(33.)-875.1 (Daru J, Fedczyna )17.7 (T)74 (, Ngai K-N, Pachman LM. Pharmacokinetics)]TJ
2.175 -1.25 Td
(studies show decreased absorption of oral methylprednisolone)Tj
T*
(compared with intravenous methylprednisolone in rheumatic)Tj
T*
(disease patients with active vasculitis [abstract]. Pediatr Res)Tj
0 Tc 0 Tw T*
(2000;47:91. )Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(34.)-875.1 (Feldman BM, Rider LG, Dugan L, Millwer FW)91.7 (, Schneider R.)]TJ
2.175 -1.25 Td
(Nailfold capillaries as indicators of disease activity in juvenile )Tj
T*
[(idiopathic inflammatory myopathies [abstract]. )54.8 (Arthritis Rheum)]TJ
0 Tc T*
(1999;42 Suppl:S181.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(35.)-875.1 (Herrick )54.8 (A, Moore )17.7 (T)74 (, Hollis S, Jayson MIV)128.8 (. )17.7 (The influence of age on)]TJ
2.175 -1.25 Td
(nailfold capillary dimensions in childhood. J Rheumatol)Tj
0 Tc 0 Tw T*
(2000;27:797-800.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(36.)-875.1 (Spencer)19.7 (-Green G, Crowe )17.7 (WE, Levinson JE. Nailfold capillary)]TJ
2.175 -1.25 Td
(abnormalities and clinical outcome in childhood dermatomyositis.)Tj
T*
(Arthritis Rheum 1982;25:954-8.)Tj
-2.175 -1.25 Td
[(37.)-875.1 (Pachman LM, Mendez E, Lechman )17.7 (T)74 (, Sundber)17.7 (g J, Shamiyeh E,)]TJ
2.175 -1.25 Td
[(Dyer )54.8 (A. )17.7 (The rash of juvenile dermatomyositis is associated with)]TJ
T*
[(derangement of capillaries [abstract]. )54.8 (Arthritis Rheum 2000;43)]TJ
0 Tc 0 Tw T*
(Suppl:S380. )Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(38.)-875.1 (Pachman LM, Fedczyna )17.7 (T)17.9 (O, Lutz JL, Caliendo J, Lechman )17.7 (T)74 (,)]TJ
2.175 -1.25 Td
(O\325Gorman MRG. Increased CD8+ and CD56+ lymphocytes in)Tj
T*
(untreated juvenile dermatomyositis muscle biopsies are associated)Tj
T*
(with a short compared with a long disease duration [abstract].)Tj
T*
(Arthritis Rheum 2000;43 Suppl:772. )Tj
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_3 1 Tf
8 0 0 8 54.5 35.9844 Tm
[(Smith, et al: Nailfold capillar)36.8 (oscopy in JDM)]TJ
0 Tc 0 Tw 60.9375 -0.0313 Td
(1649)Tj
ET
0 0 0 0 k
/GS0 gs
109.22 59.08 396.48 -10.83 re
f*
0.5 w
109.22 59.08 396.48 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_4 8 Tf
119.868 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology. Copyri\
ght \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_5 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 19, 2024 from )Tj
ET
endstream
endobj
52 0 obj
<>stream
8;Z\5$#U\:%-7FQaR:s/1l!>k=&(=a/]%Y1g>_Z?%S)r%p1s\o7HE(Xj"iI*T-%D^
f$9m`mUVSm]O8)9f/SKK[L;Ad:Bjjdg_iCkIlRkOHdu3LqSYFQRqp9h$_0i=u
8/Mf.i*710"n]nX34(C\+P#/F^X.pjL<6dUfTkC-gl#iT1J6AF=P:'/Ke1(-(l"=JF]>&l,a'.SgZ$+o;SQ4R'lPKt.9U(9
s6L8O]WNp,belj7)LRm>C`[??i.bdR@tcn+-MCHDo\D);%:fKY93&A[G2AV(=7S1oouB6ch7FEH7!n>/6*kACL)[Vccu^u3TFS`26SR
V9Z[\qRtaYI`?[F0[p=&g:2nJNV(r_c4LQ&T][*l[7XWNX"*`R$bhLP3Vickg217S
W9`^s:Nh(rS+%-80NBLo!IP^?'/oF)`bq%P[nq9CFjY#+R,oUV^=/Icl9<`u1QPKl
5b_Km6R>$I:o@^rJD.1pE]UYBjgWo#X\29OI!+%<5,-pjO-Z2+3m/MBP.Wjl(h1:h
`),)<&5F+C?6)BTaV9_CFu=G'&Y8UGU+X2A0aeZ3K,VHH3_?]V(L%O."`iE*r_mlA
GL`N&;oR]?6((mj?&c6:?@,RELrKbZeARO"W$aSV@Za
endstream
endobj
56 0 obj
[/Indexed/DeviceRGB 255 55 0 R]
endobj
55 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
129 0 obj
<>
endobj
82 0 obj
<>
endobj
86 0 obj
<>
endobj
76 0 obj
<>
endobj
116 0 obj
<>
endobj
147 0 obj
<>
endobj
75 0 obj
<>
endobj
109 0 obj
<>stream
HUiPSY}K)kVԈ::-*֍$BH aI %$ $(a ,
6 R826"0cZ3UҗgjO:u9uWu1[qۃ7l^*JJn D?׳끳smXOm9f=qޖ֢ğ4?qIFşОgg-:'qYo|oo
bG\ĊcT&L2[S$Lg#Wʤ4k0A0QrbDIb\"d63eFdIScX E$p(1}c
[l=YKôq ~&FgelͶ?g ';}EIgvavevOmfNN?4}3xx\3O!O;-u*svvrqtѻC/6-HSK2UL/MO̔f*4TAVit1r~O
:%dɝNi)djnN5ũbO]ec:^
$4Jy#ˁ$Fk1QY<Ȅ՚/Ѭd4mE+5~7~ @78Jg6S?T^C5ېcr䑐Juh肺Rry=lNPb"9eYjsyjMB~Q61SjroV`w96rc[ue'^'8c`